Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection

Stock Information for Cocrystal Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cocrystal Pharma Inc.

Cocrystal Pharma Provides Update on Reverse Stock Split
Cocrystal Pharma Announces 1-for-30 Reverse Stock Split
Cocrystal Pharma Announces Filing 2017 Third Quarter Financial Statements and Provides Company Update
Cocrystal Pharma to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York
Cocrystal Pharma, HitGen and InterX Enter into Drug Discovery Collaboration
Cocrystal Pharma Announces Filing 2017 Second Quarter Financial Statements and Provides Company Update
James J. Martin Appointed as Chief Financial Officer of Cocrystal Pharma, Inc.
Cocrystal Pharma Receives Investment Through Private Placement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.